Senate Bill 1495, also known as House Bill 1968, amends Tennessee Code Annotated to address the involvement of various pharmaceutical companies in opioid-related matters. Specifically, it updates Section 20-13-203 by removing references to "Purdue Pharma L.P." and replacing it with "Purdue Pharma L.P., Alvogen, Inc., Apotex Corp., and Zydus Pharmaceuticals (USA) Inc." Additionally, Section 33-11-103(p) is revised to include the same companies, replacing the previous mention of "Purdue Pharma LP."

The bill also includes a severability clause, ensuring that if any part of the act is found to be invalid, the remaining provisions will still be enforceable. This legislation is set to take effect immediately upon becoming law, emphasizing the urgency of addressing the opioid crisis in Tennessee.

Statutes affected:
Introduced: 20-13-203, 33-11-103(p), 33-11-103